# Gene Transfer and Somatic Cell Enginerring

> **NIH NIH P30** · SLOAN-KETTERING INST CAN RESEARCH · 2020 · $383,196

## Abstract

ABSTRACT
The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and
supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their
safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering
Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical
trials based on cell engineering and adoptive cell therapies. Its aims are as follows:
AIM1: To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2: GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks
(plasmid DNA, cell banks).
AIM3: Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability);
Gene transfer/expression.
AIM4: To monitor patients’ samples post-infusion (e.g., FACS, Q-PCR).
AIM5: To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).

## Key facts

- **NIH application ID:** 9858285
- **Project number:** 5P30CA008748-54
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** Isabelle Riviere
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $383,196
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9858285

## Citation

> US National Institutes of Health, RePORTER application 9858285, Gene Transfer and Somatic Cell Enginerring (5P30CA008748-54). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9858285. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*